H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.

Trial Details

NCT ID
NCT07501156
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Geno-Immune Medical Institute
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • H3K27M-EIEs
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Abilities to understand and the willingness to provide written informed consent;
  • ≥ 2 and ≤ 70 years old;
  • Recurrent or refractory diffuse midline glioma or diffuse intrinsic pontine glioma patients with confirmed H3K27M mutation and documented lesions. …
  • Karnofsky performance score (KPS) ≥ 60;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →